Inhibition of miR-16 Ameliorates Inflammatory Bowel Disease by Modulating Bcl-2 in Mouse Models

Chen, Ye; Shan, Ting; Qu, Huiheng; Chen, Yigang; Wang, Ning; Xia, Jiazeng

doi:10.1016/j.jss.2020.03.037

Cited by 6 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(2011) and Chen et al. (2020) revealed similar results that miR-150 or miR-16 can downregulate the expression of Bcl-2 to disrupt colonic epithelium in DSS-induced mouse IBD models ( 69 , 70 ). TGF-β may downregulate miR-29b expression, which will inhibit the gene expression of IL-6/Mcl-1 (an anti-fibrotic mediator) or the IL-8 / Mcl-1 axis, and then lead to increased collagen deposition and promote intestinal fibrosis in patients with CD ( 71 ).…”

Section: Mirnas and Pathogenesis-related Signaling Pathways In Ibdmentioning

confidence: 78%

See 1 more Smart Citation

miRNAs Can Affect Intestinal Epithelial Barrier in Inflammatory Bowel Disease

et al. 2022

View full text Add to dashboard Cite

The most obvious pathological characterization of inflammatory bowel disease (IBD) is intestinal epithelium erosion and severe inflammation invasion. Micro-ribonucleic acids (miRNA or microRNA), single-stranded noncoding RNAs of ~22 nucleotides, have been considered as the potential therapeutic targets in the pathogenesis of IBD. Many previous studies have focused on the mechanisms that miRNAs use to regulate inflammation, immunity, and microorganisms in IBD. The review highlights in detail the findings of miRNAs in the intestinal epithelial barrier of IBD, and focuses on their gene targets, signaling pathways associated with IBD, and some potential therapies. It will be beneficial for the elucidation of the interaction between miRNAs and the intestinal epithelial barrier in IBD and provide a theoretical reference for preventing and treating IBD in the future.

show abstract

Section: Mirnas and Pathogenesis-related Signaling Pathways In Ibdmentioning

confidence: 78%

“…Chen et al. (2020) indicated that the IP administration of miR-16 antagomir upregulated the Bcl-2 expression and ameliorates intestine function in 3% DSS-induced mice ( 69 ). In contrast, Zhang et al.…”

Section: Mirna-related Potential Therapies To Ibdmentioning

confidence: 99%

miRNAs Can Affect Intestinal Epithelial Barrier in Inflammatory Bowel Disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In this case, miRNAs complementary antisense oligonucleotides or miRNA mimics can be potential therapeutics that abolish or mimic miRNA’s function and, therefore, block inflammatory progression, modulate cytokines or chemokine hemostasis and increase the treatment sensitivity of conventional therapies. As such, miRNAs are used for modulating hypoxia ( 183 , 184 ) and the inflammatory response by targeting major inflammatory pathways ( 185 – 189 ) and essential molecules, including tight junction proteins that maintain the integrity of the membrane ( 74 , 190 , 191 ).…”

Section: Discussionmentioning

confidence: 99%

Differentially Expressed miRNAs in Ulcerative Colitis and Crohn’s Disease

Yarani

Shojaeian²,

Palasca³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Differential microRNA (miRNA or miR) regulation is linked to the development and progress of many diseases, including inflammatory bowel disease (IBD). It is well-established that miRNAs are involved in the differentiation, maturation, and functional control of immune cells. miRNAs modulate inflammatory cascades and affect the extracellular matrix, tight junctions, cellular hemostasis, and microbiota. This review summarizes current knowledge of differentially expressed miRNAs in mucosal tissues and peripheral blood of patients with ulcerative colitis and Crohn’s disease. We combined comprehensive literature curation with computational meta-analysis of publicly available high-throughput datasets to obtain a consensus set of miRNAs consistently differentially expressed in mucosal tissues. We further describe the role of the most relevant differentially expressed miRNAs in IBD, extract their potential targets involved in IBD, and highlight their diagnostic and therapeutic potential for future investigations.

show abstract

“…Consistently, the overexpression of miR-135a in colonic epithelial cells prevented apoptosis and inflammation by inhibiting the expression of apoptotic factor Bax and enhancing the expression of anti-apoptotic factor Bcl-2 via HIF-1α [ 131 ]. Another study found a negative correlation between miR-16 and Bcl-2 expression in Caco-2 cells and in the colonic mucosa of DSS-treated mice [ 107 ]. Further investigation in 3% DSS induced colitis mice (two weeks) with the intraperitoneal administration of anti-miR-16 (dose: 5 mg/kg, twice per week) alleviated colitis and reduced proinflammatory cytokines in comparison to PBS-treated DSS controls [ 107 ].…”

Section: Microrna As a Therapeutic Target In Ibdmentioning

confidence: 99%

“…Another study found a negative correlation between miR-16 and Bcl-2 expression in Caco-2 cells and in the colonic mucosa of DSS-treated mice [ 107 ]. Further investigation in 3% DSS induced colitis mice (two weeks) with the intraperitoneal administration of anti-miR-16 (dose: 5 mg/kg, twice per week) alleviated colitis and reduced proinflammatory cytokines in comparison to PBS-treated DSS controls [ 107 ].…”

Section: Microrna As a Therapeutic Target In Ibdmentioning

confidence: 99%

Role of MicroRNA in Inflammatory Bowel Disease: Clinical Evidence and the Development of Preclinical Animal Models

Suri

Bubier

Wiles

et al. 2021

Cells

View full text Add to dashboard Cite

The dysregulation of microRNA (miRNA) is implicated in cancer, inflammation, cardiovascular disorders, drug resistance, and aging. While most researchers study miRNA’s role as a biomarker, for example, to distinguish between various sub-forms or stages of a given disease of interest, research is also ongoing to utilize these small nucleic acids as therapeutics. An example of a common pleiotropic disease that could benefit from miRNA-based therapeutics is inflammatory bowel disease (IBD), which is characterized by chronic inflammation of the small and large intestines. Due to complex interactions between multiple factors in the etiology of IBD, development of therapies that effectively maintain remission for this disease is a significant challenge. In this review, we discuss the role of dysregulated miRNA expression in the context of clinical ulcerative colitis (UC) and Crohn’s disease (CD)—the two main forms of IBD—and the various preclinical mouse models of IBD utilized to validate the therapeutic potential of targeting these miRNA. Additionally, we highlight advances in the development of genetically engineered animal models that recapitulate clinical miRNA expression and provide powerful preclinical models to assess the diagnostic and therapeutic promise of miRNA in IBD.

show abstract

Inhibition of miR-16 Ameliorates Inflammatory Bowel Disease by Modulating Bcl-2 in Mouse Models

Cited by 6 publications

References 34 publications

miRNAs Can Affect Intestinal Epithelial Barrier in Inflammatory Bowel Disease

miRNAs Can Affect Intestinal Epithelial Barrier in Inflammatory Bowel Disease

Differentially Expressed miRNAs in Ulcerative Colitis and Crohn’s Disease

Role of MicroRNA in Inflammatory Bowel Disease: Clinical Evidence and the Development of Preclinical Animal Models

Contact Info

Product

Resources

About